Mechanism of action of dextromethorphan/quinidine: Comparison with ketamine

CNS Spectrums

Volumn 18, Issue 5, 2013, Pages 225-227

  Stahl, Stephen M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEXTROMETHORPHAN; DEXTROMETHORPHAN PLUS QUINIDINE; KETAMINE;

ARTICLE; BINDING AFFINITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; PRIORITY JOURNAL;

DEXTROMETHORPHAN; DRUG COMBINATIONS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MOOD DISORDERS; QUINIDINE;

EID: 84884626301     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285291300062X     Document Type: Article

References (10)

1. Prescribing information, Nuedexta Package insert, 2013.
2. Pioro EP, Brooks BR, Cummings J, et al. Safety, tolerability, and efficacy results trial of AVP-923 in PBA investigators dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010; 68(5): 693-702.
3. Brooks BR, Thisted RA, Appel SH, et al. AVP-923 ALS study group treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004; 63(8): 1364-1370. (Pubitemid 39426266)
4. Stahl SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.
5. Roth BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP), Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD, at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details, please refer to the PDSP Web site: http://pdsp.med.unc.edu
6. Stahl SM. Mechanism of action of ketamine. CNS Spectr. 2013; 18: 171-174.
7. Bunney BG, Bunney WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol. 2012; 15: 695-713.
8. Ibrahim L, DiazGranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012; 37(6): 1526-1533.
9. Hayashi T, Stahl SM. Sigma 1 receptor and its role in the treatment of mood disorders. Drugs of the Future. 2009; 34: 137-146.
10. Stahl SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition J Clin Psychiatry. 2008; 69: 1673-1674.